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Abstract
Butyrate, a known histone deacetylase inhibitor (HDACi) and product of fibre fermentation, is postulated to med-
iate the protective effect of dietary fibre against colon cancer. The transcription factor Sp1 is a target of acetylation
and is known to be associated with class I HDACs, including HDAC1. Sp1 is a ubiquitous transcription factor and
Sp1-regulated genes include those involved in cell cycle regulation, apoptosis and lipogenesis: all major pathways
in cancer development. The only known acetylated residue of Sp1 is lysine703 which resides in the DNA binding
domain. Here we show that acetylated Sp1 loses p21- and bak-promoter -binding function in vitro. Furthermore
treatment with a panel of HDAC inhibitors showed clustering of activities for a subset of inhibitors, causing G2 cell
cycle arrest, Sp1 acetylation, p21 and Bak over-expression, all with very similar EC50 concentrations. These HDACi
activities were not distributed according to the molecular class of compound. In order to mimic loss of binding, an
siRNA strategy was used to reduce Sp1 expression. This resulted in altered expression of multiple elements of the
p53/p21 pathway. Taken together our data suggest a mechanistic model for the chemopreventive actions of buty-
rate in colon epithelial cells, and provide new insight into the differential activities some classes of HDAC inhibitors.
Introduction
It is now widely recognised that histone acetyltrans-
ferases (HATs) and histone deacetylases (HDACs) have
non-histone substrates and can modulate transcription
by directly acetylating/deacetylating transcription fac-
tors and associated cofactors [1]. Two members of the
Sp transcription factor family, Sp1 and Sp3, have been
reported to be acetylated [2,3]. Alanine scanning muta-
genesis identified lysine-703 (K703) as a target of acet-
ylation in Sp1 [3]. Sp1 K703A mutants showed no
detectable acetylation suggesting that acetylation only
occurs at this single site. Sp3 has also been reported to
be acetylated at a specific residue in its C-terminal
inhibitory domain, however mutants lacking this
domain were still acetylated, therefore Sp3 probably
has other residues which are acetylated [2]. The func-
tional relevance of this post-translational modification
is unclear from the literature. The location of the Sp1
K703 acetylation site in the DNA binding domain sug-
gests acetylation of Sp1 could affect DNA binding and/
or gene transactivation. Initial findings indicated that
acetylation may increase Sp-mediated transcription [4].
However, the simplistic ‘more acetylation results in
more transcription’ model has been disputed by recent
findings. Expression of a recombinant Sp1 mutant
(K703A), which could not be acetylated, resulted in
increased expression of the lipoxygenase (12-LOX)
gene [3] whilst treatment with HDAC inhibitors atte-
nuated the expression of COX-2 in HT29 cells and
IGFBP3 in CaCo2 cells [5,6]. It is possible that compe-
tition between Sp1 and Sp3 for GC-box binding sites,
could be swayed by acetylation. In support of this, Sp3,
which is normally a weak transcriptional activator, was
able to, in the absence of acetyltransferases, function
as a transcriptional activator with similar potency to
Sp1 [7]. Small alterations in Sp1/Sp3 binding affinity
could result in altered occupancy at the promoter and
alter the gene expression according to whether the
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sor. Chromatin immunoprecipitation (ChIP) assays
have demonstrated a reduction in binding of Sp1
accompanied by an increase in Sp3 binding at the
major vault protein promoter following treatment with
the HDAC inhibitors TSA and butyrate [8]. A similar
switch of Sp1 for Sp3 has been observed at the promo-
ter for the pro-apoptotic protein BAK following buty-
rate treatment [9].
Sp1 and Sp3 are reported to be associated with HDAC1
and HDAC2 [10,11]. HDAC1 may be present in a large
multimeric complex with Sp1, Sp3 and p300 during
IGFBP-3 activation [12]. HDAC1 also binds directly to
Sp1 zinc fingers, however, this is a deacetylase activity-
independent event [13]. Taken together these data sup-
port a role for HDAC1 and HDAC2 in the deactylation
of Sp1 and Sp3. Overexpression of class I and II HDACs
has been observed in a number of cancers including gas-
tric [14], lung [15], breast[16], colon [17], and ovarian
cancers [18]. These observations have led to interest in
HDAC inhibitors as potential therapeutic targets, with
emphasis on development of novel HDAC inhibitors
(HDACi).
HDAC inhibitors have been studied for several years.
Butyrate, a by-product of fibre fermentation in the colon
was characterised as a promoter of histone acetylation in
1977 [19]. Several other naturally occurring HDACi have
been identified, including trapoxin and valproic acid.
There is a substantial academic and industrial effort to
develop inhibitors with HDAC-specific activity. Several
classes of compounds have HDACi activity, including
short-chain fatty acids, such as butyrate, branched chain
fatty acids, hydroxamic acids and others (see Additional
File 1, Table 1). The different classes of inhibitors have
variable and overlapping specificity for each HDAC,
although with the exceptions of tubacin (HDAC 6 speci-
fic) and cambinol (Sirtuin class 1/2 specific), none are
truly specific. Most HDACi act against several members
of each subclass of HDACs, and several of the hydroxa-
mic acids are active against all Class I and II HDACs.
Likewise nicotinamide is a pan-specific inhibitor of
the sirtuin HDAC subfamily. Several clinical trials, par-
ticularly for cancer therapy, are underway to examine
therapeutic benefits of HDACi. The HDAC inhibitor
Vorinostat (suberoylanilde hydroxamic acid, SAHA), has
been approved for treatment of cutaneous T cell lym-
phoma [20]. In many of these trials the HDACi is used as
a combination therapy with a first-line chemotherapeutic
in order to improve efficacy. Trials are in progress for
both short and branched chain fatty acids, hydroxamic
acids and cyclic tetrapeptides [reviewed in [21] and [22]].
In addition its to pharmacological relevance, butyrate
occurs naturally in the colon, at pharmacologically active
concentrations (0.5-20 mM) as a by-product of fibre
fermentation and is thought to be responsible for protec-
tion against colorectal cancer conferred by high fibre
diet [23,24].
Despite widespread interest in the development of
HDACi as therapeutics, their mechanism of action is
not fully understood. Piecemeal reports using one or
two HDACi in single cell lines indicate that most of
these compounds will drive both cell cycle arrest and
apoptosis in vitro. Work using isogenic colon cell lines
has revealed that p21 is essential for normal cell cycle
arrest following butyrate treatment and several publica-
tions show that this occurs via a p53 independent path-
way [25]. Our work and that of others has shown that
the pro-apoptotic protein Bak is up-regulated following
butyrate treatment of colon cell lines [9,26,27] and again
that this occurs via a p53-independent route [26]. We
have hypothesized that Bak upregulation is essential for
butyrate-induced apoptosis [28]. Both p21 and Bak are
up-regulated by reduction in Sp1 binding [9,29,30] and
we now report here that acetylation of Sp1 following
treatment of cells with the HDACi butyrate reduced Sp1
binding to p21 and bak promoter sequences. These data
imply a common mechanism for cell cycle arrest and
apoptosis following butyrate. Recent reviews of the
mechanism of action of HDACi in general have been
inconclusive, although other work has speculated that
the cancer therapeutic actions of HDACi may also be a
result of suppression of angiogenesis [31].
We hypothesized that up-regulation of p21 and Bak in
response to the HDACi butyrate may have a common
mechanism related to the biological regulation of their
common transcriptional activator Sp1. Acetylation of
Sp1 is a candidate mechanism for this regulation. Owing
to the conflicted literature and potential physiological
and pharmacological importance of this target, we inves-
tigated the effect of Sp1 acetylation on function in colon
epithelial cells.
Results
Sp1 is acetylated in colon cells and its acetylation
increases following treatment with the HDACi, sodium
butyrate
Several previous reports indicate Sp1 acetylation is a
determinant of DNA binding activity. In order to assess
whether Sp1 is acetylated in the HCT116 colon cell line,
the protein was immunoprecipitated (IP) using an anti-
Sp1 antibody and the precipitate analysed by western
blot and immunoprobing with anti-Sp1 and anti-acetyl
lysine antibodies (see Additional File 1, Fig 1). This
approach showed the predicted enrichment of Sp1 in the
IP fraction. When the IP was immunoprobed with an
anti-acetyl antibody, a cross-reaction occurred in the IP
fraction at the same molecular weight as Sp1, suggestive
of acetylation of this protein.
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ated an antibody to the published acetyl-Sp1 epitope
(K703). The antibody was double-affinity purified (coun-
ter-purified against the non-acetyl epitope, then purified
against the K703 epitope). The antibody (K703-Sp1),
cross-reacted with a single band of the same molecular
weight as Sp1 in whole cell lysates, did not cross-react
in lines not expressing Sp1 and also detected immuno-
precipitated Sp1 (see Additional File 1, Fig1).
The novel anti-acetyl-Sp1 antibody was used in a
high-content analysis (HCA) approach to assess the
effect of increasing concentrations of the HDACi buty-
rate upon Sp1 acetylation and expression of known Sp1
targets p21 and BAK. Relative Sp1, acetyl-Sp1, p21 and
BAK expression levels were obtained using high-content
analysis as described in the methods section. Sp1
expression levels were essentially constant (Fig 1Ai) fol-
lowing butyrate treatment, however acetyl-Sp1 levels
increased in a concentration-dependent manner in
response to butyrate treatment (Fig 1Aii). Expression of
both Bak (Fig 1Aiii) and p21 (Fig 1Aiv) also demon-
strated a concentration-responsive increase following
butyrate treatment, and in line with Sp1 acetylation.
The EC50 for Sp1 acetylation, Bak and p21 up-regulation
are estimated in the table in Fig 1Av. The EC50 for all
events are similar, particularly so for Sp1 acetylation
and Bak up-regulation. The co-linearity of up-regulation
suggests that both Bak and p21 up-regulation may be a
consequence of Sp1 acetylation.
When images of cells dual-stained for acetyl-Sp1 and
p21 were examined from cultures before and after buty-
rate treatment there was marked difference in level of
acetyl-Sp1 cross-reaction and in expression and localisa-
tion of p21. In untreated cells there was little or no
acetyl-Sp1 staining and most p21 cross-reactivity was
cytosolic (Fig 1Bi). Following treatment with 10 mM
butyrate for 24 h, there was a clear increase in acetyl-Sp1
staining, which was nuclear, and an increase in nuclear
p21 staining. The merged image of p21 (red) and acetyl-
Sp1 (green) staining revealed that most nuclei either
appeared green (arrows marked i) or yellow-orange
(arrows marked ii) with few or no nuclei staining red,
indicating p21 colocalises with acetyl-Sp1 in the nucleus.
In order to quantitate this observation, we plotted the
percentage of cells positive for p21, which also stained
for acetyl-Sp1 and vice versa (Fig 1Bii; the gating strategy
is shown in the Additional File 1). This plot revealed that
the majority (>91%) of p21-positive nuclei were also
acetyl-Sp1 positive. In contrast, only 40% of acetyl-Sp1
positive cells were p21-positive, demonstrating that acet-
ylation of Sp1 occurred without increased p21 expres-
sion. Taken together, we infer that following butyrate
treatment, Sp1 acetylation precedes p21 up-regulation.
Acetylation of Sp1 eliminates in vitro binding of promoter
sites to two Sp1-regulated genes
T h el o c a t i o no fK 7 0 3i nt h eSp1 DNA-binding domain
led us to ask whether acetyl-Sp1 retains its DNA-binding
Table 1 List of genes in the p53-p21 pathway downregulated following Sp1 knockdown
Probe Set
ID
Gene Title Gene Symbol 48 hr post Sp1
knockdown
72 hr post Sp1
knockdown
Fold
change
Regulation Fold
change
Regulation
1556990_at PERP, TP53 apoptosis effector PERP 2.87 down 2.46 down
211725_s_at BH3 interacting domain death agonist BID 1.78 down 1.85 down
227143_s_at BH3 interacting domain death agonist BID 1.64 down 1.70 down
204493_at BH3 interacting domain death agonist BID 1.82 down - No change
209644_x_at cyclin-dependent kinase inhibitor 2A (p16) CDKN2A
(p14ARF)
1.53 down 1.51 down
207039_at cyclin-dependent kinase inhibitor 2A (p16) CDKN2A
(p14ARF)
1.58 down - No change
224851_at cyclin-dependent kinase 6 CDK6 1.40 down - No change
209305_s_at growth arrest and DNA-damage-inducible, beta GADD45B 1.31 down - No change
214710_s_at cyclin B1 CCNB1 1.30 down - No change
204315_s_at G-2 and S-phase expressed 1 GTSE1 (B99) 1.23 down - No change
218424_s_at STEAP family member 3 STEAP3
(TSAP6)
1.22 down - No change
236814_at Mdm4, transformed 3T3 cell double minute 4, p53 binding
protein (mouse)
MDM4 1.73 down - No change
225740_x_at Mdm4, transformed 3T3 cell double minute 4, p53 binding
protein (mouse)
MDM4 - No change 1.74 down
202763_at caspase 3, apoptosis-related cysteine peptidase CASP3 - No change 1.29 down
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used sequences from the Bak and p21 promoters, which
are known to bind Sp1 [9,32]. These sequences contain
several potential and confirmed Sp1/3 binding sites
(Fig 2A). Western blots of mobility shift gels (WeMSAs)
were undertaken before and after butyrate treatment
with both bak and p21 probes. When mobility shift
gels were immunoprobed for Sp1, a characteristic cross-
reaction was observed (Fig 2B), which decreased with
both probes after butyrate treatment. When identical
gels were probed with anti-acetyl-Sp1 antibody no cross-
reactions were ever observed, despite repeated efforts.
The WeMSA method works in our hands (as we can
get cross-reaction with Sp1, or Sp3) and the acetyl-Sp1
antibody appears to work in some applications (as con-
ventional SDS-PAGE immunoblotting works with the
antibody), and so we interpret these data as showing
that the intracellular pool of acetyl-Sp1 has little or no
Table 2 List of genes in the p53-p21 pathway upregulated following Sp1 knockdown
Probe Set ID Gene Title Gene Symbol 48 hr post Sp1
knockdown
72 hr post Sp1
knockdown
Fold change Regulation Fold change Regulation
220403_s_at p53-regulated apoptosis-inducing protein 1 P53AIP1 2.76 up - No change
202627_s_at serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1), member 1
SERPINE1 (PAI) 2.01 up 2.43 up
230330_at protein phosphatase 1D magnesium-dependent,
delta isoform
PPM1D (WIP-1) 1.86 up - No change
204566_at protein phosphatase 1D magnesium-dependent,
delta isoform
PPM1D (WIP-1) 1.72 up 1.52 up
202284_s_at cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 1.84 up 1.96 up
1555186_at cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A - No change 1.25 up
203409_at damage-specific DNA binding protein 2, 48kDa
(p48 subunit)
DDB2 1.79 up - No change
204859_s_at apoptotic peptidase activating factor 1 APAF1 1.76 up - No change
218346_s_at sestrin 1 SESN1 1.74 up 1.56 up
204285_s_at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 (NOXA) 1.48 up 1.60 up
204286_s_at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 (NOXA) - No change 1.55 up
204781_s_at Fas (TNF receptor superfamily, member 6) FAS 1.73 up 1.59 up
215719_x_at Fas (TNF receptor superfamily, member 6) FAS 1.47 up 1.35 up
204780_s_at Fas (TNF receptor superfamily, member 6) FAS 1.43 up 1.45 up
216252_x_at Fas (TNF receptor superfamily, member 6) FAS 1.41 up - No change
208712_at cyclin D1 CCND1 1.46 up 1.39 up
208711_s_at cyclin D1 CCND1 1.34 up - No change
201700_at cyclin D3 CCND3 1.42 up - No change
222986_s_at scotin SCOTIN 1.40 up - No change
242899_at sestrin 3 sesn3 1.38 up - No change
241015_at sestrin3 sesn3 - No change 1.43 down
208796_s_at cyclin G1 CCNG1 1.38 up - No change
229415_at cytochrome c, somatic CYCS 1.35 up - No change
211711_s_at phosphatase and tensin homolog PTEN 1.25 up - No change
238075_at CHK1 Checkpoint homolog (S.Pombe) CHK1 1.23 up - No change
202981_x_at seven in absentia homolog 1 (Drosophila) SIAH1 1.20 up - No change
209260_at stratifin SFN (14-3-3s) 1.33 up - No change
33323_r_at stratifin SFN (14-3-3s) - No change 1.43 up
33322_i_at stratifin SFN (14-3-3s) - No change 1.35 up
213523_at cyclin E1 CCNE1 - No change 1.34 up
204855_at serpin peptidase inhibitor, clade B (ovalbumin),
member 5
SERPINB5 (Maspin) - No change 1.32 up
201110_s_at thrombospondin 1 THBS1 (TSP1) - No change 1.32 up
211692_s_at BCL2 binding component 3 BBC3 (PUMA) - No change 1.23 up
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other Sp1 species may retain binding affinity.
We undertook a concentration-response study to
establish the range of butyrate concentrations which
would cause a reduction in Sp1 binding and to establish
whether any underlying alteration in Sp1 levels may be
associated with the observed decrease in binding.
Nuclear extracts prepared from 0-20 mM butyrate
Figure 1 Sp1 acetylation increases in a co-linear manner with bak and p21 expression following sodium butyrate treatment.H C T 1 1 6
cells were treated with increasing concentrations of butyrate (0-20 mM) for 24 hr, fixed and fluorescence immunostained either for Sp1 and Bak
or Ace-Sp1 and p21. Cellular fluorescence was quantified by High-Content Analysis. Panel A shows protein expression levels of Sp1 (Panel Ai);
acetyl-Sp1 (Panel Aii); Bak, (Panel Aiii) and p21 (Panel Aiv). Data are from a single pass experiment with three replicates, with 50 fields per
replicate scored. The EC50 value for each event in response to butyrate is shown in Panel Av. Panel B shows representative images of HCT116
cells following 24 h of 0 or 10 mM sodium butyrate treatment and fluorescence immunostaining for acetyl-Sp1 and p21. Panel Bi shows
representative fields from the control (untreated) cells (upper panel) and the treated culture (lower panel). Staining patterns in the treated cells
broadly fell into two main types, cell positive for acetyl-Sp1 alone (examples marked by arrows i) and cells positive staining for both acetyl Sp1
and p21 (marked by arrows ii). These subpopulations were distinguished by plotting acetyl-Sp1 vs. p21 fluorescence (see supplementary online
data Fig 2 for gating strategy). Panel Bii shows quantitation of data from three independent experiments, showing numbers of cells in gated
fractions that were dual stained, as indicated.
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binding activity using the same approach. Total levels of
Sp1 expression were also measured by western blotting
the extracts. Data are shown in Fig 2C. Increasing buty-
rate concentration caused a progressive decrease in
binding of Sp1 to both the bak (Fig 2Ci - upper panel)
and p21 (Fig 2Cii - upper panel) target sequences. The
reduction in binding could not be explained by signifi-
cant reduction in Sp1 basal levels, which were broadly
unaltered by butyrate (Fig 2Ci and 2Cii lower panels).
A
BAK
+1
SpA SpB SpC
-194GCCTGGGAGGTGGGGTGGGGAAAGTGGGCGGGAC
ATGCTCCTGGGCCTGGCCCACCCAGA-134
-125CGGGGAGGGCGGTCCCGGGCGGCGCGGTGGGC
CGAGCGCGGGTCCCGCCTCCTTGAGGCGGGCCCGG
GCGGGGCGGTT -48
+1
Sp1 Sp2
P21
Sp3 Sp4 Sp5/6
-50 -119
-137
-190
C
Sp1 Shift
Bak probe
0
0
.
5
1
5
1
0
2
0
mM Butyrate
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B
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01 0 0 1 0 0 1 0
p21 Bak No 
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Sp1
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100kDa
Figure 2 Acetylated Sp1 does not bind at the bak or p21 promoters. Panel A shows the organisation and sequence of the bak (Ai) and p21
(Aii) probes, with hypothetical and proven Sp1/3 binding sites underlined. Sequence numbers refer to distance from the transcriptional start site
of each gene. Panel B shows that binding of Sp1 to both target sequences is decreased following butyrate treatment. Panel B: Western of
mobility shift assay (WeMSA) analysis of binding to the Bak and p21 probes shows that Sp1 binding decreases following treatment with 10 mM
sodium butyrate for 24 h compared to an untreated control (upper panel). Binding of acetyl-Sp1 could not be detected by WeMSA (lower
panel). These data are representative of three independent repeats. Panel C: The binding of Sp1 to the bak (panel Ci) and p21 (panel Cii)
promoter sequences was determined following treatment of HCT116 cells with a range of butyrate concentrations (0-20 mM). The upper panels
show WeMSA gels immunoprobed for Sp1. As a loading control, the same extracts were also separated by SDS page, and immunoprobed with
the same antibody (lower panels). Data shown in Ci and Cii are representative of at least two independent repeat experiments. Panel Ciii shows
mean (+/- SD) of response at the Bak promoter. Whilst the levels of Sp1 are broadly constant, levels of Sp1 binding for both probes are reduced
following treatment with butyrate.
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We noted that the relative concentration required to
reduce the binding of Sp1 to the promoter was lower for
p21 that for BAK. This may be a consequence of differing
affinity of Sp1 for these sequences, or a sub-optimal
choice of target sequence for the assay. When trying to
undertake loading validation with a series of standard
loading controls we noted many of the proteins used to
standardise loading of nuclear extract were themselves
altered by butyrate, although underlying protein levels
were constant as measured by coomassie-stained gels
(these data are shown in Additional File 1, Fig 3).
Several HDACi induce cell cycle arrest in G2/M, at
concetrations associated with Sp1 acetylation and p21
and Bak upregulation
In order to address whether the response to butyrate was
representative of the effects of HDACi, we examined the
cellular response to other HDAC inhibitors. The HDACi
in this study are listed in the Additional File 1, Table 1,
and include a variety of HDACi structure classes and
inhibition profiles. The five HDACi selected for this
study were butyrate, valproic acid (VPA), oxamflatin,
scriptaid, 3-(1-Methyl-4-phenylacetyl-1H-2-pyrrolyl)-N-
hydroxy-2-propenamide (APHA compound 8) and the
SAHA analogue, (2E,4E)-6-(4-Chlorophenylsulfanyl)-2,4-
hexadienoic acid hydroxyamide (CHAHA). These
HDACi were used to treat HCT116 cells across a range
of concentrations chosen on the basis of published data
and spanning a 2-log scale for each compound. Cells
were treated for 24 h, then fixed and stained as described
in the methods section before analysis by HCA. Multiple
cellular outcomes (cell cycle, p21 expression, Bak expres-
sion, PARP cleavage, Sp1 expression and Sp1 acetylation)
were measured in a single pass of the experiment, which
included 3 internal replicates.
Our previous work on butyrate has indicated an accu-
mulation of cells in G2/M following treatment with con-
centrations above 0.5 mM [34] although there are also
publications to suggest that butyrate triggers arrest in G1
[31,33]. In this study we found clear evidence of G2/M
phase arrest with butyrate in the 1-2 mM range which
increased with drug concentration up to 10 mM without
obvious saturation (Fig 3). In marked contrast the
branched chain fatty acid (BCFA) valproic acid (VPA)
seemed to have no effect in this concentration range with
no marked alteration in cell cycle profile even up to treat-
ment at 10 mM. Four different hydroxamic acid deriva-
t i v e sw e r eu s e di nt h i ss t u d y : oxamflatin, scriptaid,
CHAHA and APHA compound 8. Even within a group
of HDACi with common conserved molecular origin,
there were distinct differences in the effects upon cell
cycle: oxamflatin and scriptaid both induced a G2/M
arrest in cells, whereas CHAHA and APHA compound 8
induced a less pronounced G1 arrest. We noted that
there was a peak and the strength of effect was reduced
at high doses for oxamflatin and scriptaid. The G1 arrest
triggered by APHA compound 8 was only clear at low
doses and at higher doses no effect was noted.
Concomitant with analysis of effects on cell cycle and
identification of distinct responses from subsets of
HDACi, the response of p21 to multiple HDACi was
tested. Cells were treated over the established concentra-
tion range and p21 levels determined by HCA. Several of
the HDACi induced p21 expression in a concentration
responsive manner, with maximum effects observed at
the highest doses: butyrate induced a 2.27 (+/- 0.20 SEM)
average increase in p21 relative to untreated cells; val-
proic acid (VPA) also induced a near 2 fold increase
(mean 1.91+/-0.08 SEM); the hydroxamic acid, scriptaid
produced a much larger average relative increase in p21
of 4.25+/-0.21 SEM at the maximum dose used; oxamfla-
tin, also increased p21 in a concentration-responsive
manner, however the effect peaked at 5 nM (mean 1.91
fold increase +/- 0.16 SEM) and was reduced at higher
doses, indicating potential toxicity. Treatment of
HCT116 cells with APHA compound 8 had no effect on
p21 expression at the concentrations used. Low concen-
trations of CHAHA treatment produced a slight decrease
in p21 protein levels relative to untreated cells, which
corrected to baseline at higher doses.
The response of Bak to HDACi was also examined. As
was the case for p21 and cell cycle, cells were treated
over the established concentration range and Bak pro-
tein levels determined by HCA. The HDACi produced
similar effects on Bak expression as those seen for p21.
VPA, Scriptaid and oxamflatin produced increases of
approximately 3 fold in Bak expression. Butyrate
induced a marginally larger increase in Bak protein
levels of 3.5 fold, compared to untreated cells. APHA
compound 8, consistent with the results for p21, pro-
duced no significant change in expression. CHAHA
treatment produced a negligible decrease in expression,
similar to that observed for p21. Transcription of both
p21 and Bak is known to be regulated by Sp1. Therefore
we examined the levels of total Sp1 and acetylated Sp1
using the acetylated K703-Sp1 antibody. Levels of Sp1
protein remained constant following treatment with all
of the HDAC inhibitors tested( s e eF i g3 ) .I nc o n t r a s t
Sp1 acetylation increased in response to several HDACi,
notably scriptaid (maximum concentration produced a
4.02 fold mean increase +/-0.25 SEM), butyrate and
oxamflatin (maximum concentrations produced 2.49
fold mean increase +/-0.08 SEM and 2.71 +/-0.09 SEM
respectively) and CHAHA and VPA (maximum concen-
trations resulted in 2.10 fold mean increase +/-0.09
SEM and 2.10 +/-0.04 SEM). There was little detectable
response of Sp1 acetylation to APHA except at the
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by a modest mean 1.4 fold (+/- 0.04 SEM).
To assess whether the HDACi were inducing apopto-
sis at this timepoint, PARP cleavage was scored in
response to all concentrations of each drug used. Whilst
most of the HDACi induced apoptotis at levels of 2-5%
and little over background, oxamflatin and scriptaid
induced PARP cleavage in 10-15% of cells, suggesting a
potentially faster mechanism of action that we and
others have previously shown for butyrate [9,34]. Data
are shown in the Additional data file, Fig 4.
Acetylation of Sp1 precedes p21 upregulation in
response to all HDACi
There was a notable concomitance between the observed
effects of the HDACi group on Sp1 acetylation, p21
Figure 3 Effect of HDACi on cell cycle, p21 expression, bak expression and Sp1 expression and acetylation. The extent of the
concomitant response of Sp1 acetylation, cell cycle arrest and p21 up-regulation was determined using a high-content biology approach.
HCT116 cells were treated with concentration ranges of 0-20 mM sodium butyrate, 0-20 mM valproic acid (VPA), 0-20 μM Oxamflatin, 0-20 μM
Scriptaid, 0-20 μM APHA compound 8, 0-20 μM CHAHA. In all cases treatments were carried outfor 24 h. Cells were stained using
immunocytochemistry for DNA content (Hoescht), p21, bak, Sp1 and acetyl-Sp1 as described in the methods section. Cells were analysed, on the
basis of DNA content, for cell cycle phase and divided into G1 (filled circles), S (filled squares) or G2/M (filled triangles). Levels of protein were
calculated from mean total fluorescence and are expressed in terms of fluorophore fluorescence relative to that observed in untreated cells. Sp1
(filled squares) and acetyl-Sp1 (open squares) are shown on the same graph.
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Page 8 of 16expression and G2/M phase cell cycle arrest. The EC50
for each event and for each compound was calculated
and is shown in Fig 3A. There is also similarity between
the EC50s for Sp1 acetylation, p21 up-regulation and G2
arrest.
Following the concentration-response experiments,
concentrations of the HDACi approximating to the
EC50s for cell cycle arrest, Sp1 acetylation and p21 upre-
gulation were chosen, as indicated in Fig 4A, for use in a
timecourse study. As p21 plays an important role in regu-
lation of the cell cycle we anticipated that its expression
would vary as the cells approached confluency. Therefore
all experiments were carried out on subconfluent cells.
When carrying out a time course we also chose to look at
0-6 hours of treatment to identify early changes preced-
ing, rather than consequential to, cell cycle impairment.
T h et i m ec o u r s e( s e eF i g4 B )d e m o n s t r a t e dt h a ta l l
HDACi induced an increase in acetylated Sp1 when com-
pared to a time matched control. There was no increase
in total Sp1 cross-reactivity, confirming it was a change
in acetylation being observed rather than increased
expression. This increase in acetylation of Sp1 was a very
rapid event with a clear increase observable in as little as
10 minutes of treatment. The up-regulation of p21 was
examined across the same period. There was no increase
in p21 expression in response to any of the HDACi with
0-6 hours of HDACi treatment. These data agree with
the findings presented in Fig 1 that Sp1 acetylation may
precede p21 up-regulation. The data suggest that, in con-
trast to the 24 h time-point used in the concentration-
response experiment (Fig3), the HDACi tested all induce
Sp1 acetylation but that this induction is transient for
some compounds (notably CHAHA and APHA) and,
given the stark differences in cell cycle events, the differ-
ential effect results in downstream activation of distinct
pathways.
Mimicking Sp1 acetylation using siRNA knockdown
targets the p53/p21 pathway
Our experiments indicated that acetylation of Sp1 at K703
altered the binding affinity of Sp1 by abolishing binding
activity to the Bak and p21 promoters. We next sought to
investigate what effects acetylation of Sp1 might have on
the wider regulation of genes whose expression was regu-
lated by Sp1. Initially we intended to use siRNA mediated
knockdown of HDACs to identify the effector of Sp1 acet-
ylation and to increase acetylation of Sp1. However our
work indicated that siRNA knockdown of HDACs induced
compensatory mechanisms upregulating expression of
other HDACs (data not shown). Therefore to identify
further gene targets of Sp1 affected by acetylation we used
siRNA knockdown of Sp1 to mimic the abolished Sp1
binding observed following acetylation. The workflow for
this study is shown in Figure 5A.
Three predesigned Sp1 siRNAs from Ambion were
tested for efficiency of knockdown, off- target effects
and alterations in cell growth. The most effective oli-
gonucleotide, which did not noticeably affect cell
growth, was chosen for subsequent experiments. This
siRNA was used to transfect HCT116 cells. Success of
the transient Sp1 knock-down was verified by q-RT-
PCR for Sp1 (Figure 5B). Two biological replicates of
t h ee x p e r i m e n tw e r eu s e df o ram i c r o a r r a ya n a l y s i s .
The average percentage of genes described as present
on the GeneChips for the 48 h and 72 hour mock
transfected samples were 40.05% and 41% respectively.
Sp1 knockdown samples produced a similar level of
present calls with an average of 40.8% and 39.3%, at 48
and 72 h post transfection. Expression analysis was
carried out using the PLIER algorithm within the
ArrayAssist programme (Affymetrix). Probes whose
signal intensities were below the average background
level were disregarded. A gene list was compiled of
genes with a p value of ≤0.05 and a fold change of
≥1.2, relative to the mock control for each time point
(see Tables 1 and 2). These differentially expressed
genes were analysed using the functional annotation
tool of the DAVID Bioinformatics Resource. This ana-
lysis identified a number of pathways which contained
a significant number of differentially expressed genes
including: p53 signalling, cancer, apoptosis and cell
cycle pathways. The p53 signalling pathway was the
only pathway which was identified as being altered in
both the 48 h and 72 h datasets. Therefore for the pur-
poses of this study we focused our subsequent analysis
on the p53 signalling pathway, which included p21,
consistent with our earlier findings. The approximately
2 fold upregulation in p21 expression observed by the
microarray analysis was confirmed by QPCR (Fig 5D).
This QPCR analysis highlighted the variation in
expression changes between biological replicates; this
is likely due to the heterogenous nature of transient
siRNA knockdown cultures. However both biological
replicates showed increased p21 expression relative to
the time matched, mock-transfected controls for each
timepoint. To validate further the microarray results,
the expression of three other genes from the p53/p21
pathway, Bid, Serpine and P53AIP, were also checked
by QPCR (Fig 5D). In concurrence with the microarray
data, both biological replicates showed downregulation
of Bid following Sp1 knockdown at both 48 (69.7% and
44.4% of mock expression) and 72 hours (79.4%; 76.5%
of mock expression) post transfection (Sp1 knockdown
increased Serpine mRNA levels at 48 h post tranfec-
tion to 2.03 fold (replicate 1) and 2.00 fold (replicate
2) of those observed in mock transfected samples.
Serpine mRNA expression levels were also increased at
72 hours post Sp1 knockdown, however the biological
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Page 9 of 16replicates showed considerable variation: replicate 1,
3 . 4 8 %i n c r e a s er e l a t i v et om o c k ;r e p l i c a t e2 ,1 . 2 4 %
increase relative to mock. The variation in fold
changes for Serpine, observed between the biological
replicates, again reflects the heterogenicity of transient
siRNA knockdown cultures.
P53AIP showed variable levels of up regulation 48
hours post knockdown (1.2-2.4 fold up). At 72 hours
Figure 4 Acetylation of Sp1 precedes p21 up-regulation in response to all HDACi.P a n e lAs h o w sE C 50 values calculated from the
concentration-response data shown in Fig 2, for each of Sp1 acetylation and p21 upregulation. There was generally close agreement between
these values. The third column indicates the concentration used in subsequent timecourse experiments. Panel B shows timecourse experiments.
HCT116 cells were treated with concentrations of HDACi as indicated in panel A, for times from 0 to 6 h. Timepoints less that 1 h are 10 min
and 30 min. Cells were fixed and stained for acetyl-Sp1 and for p21 as before. Fluorescences were quantitated using high content approaches.
Graphs are for acetyl-Sp1 (filled squares) p21 (filled triangles) and total Sp1 (filled diamonds). The results show the means of three repeat
experiments with internal triplicates.
Waby et al. Molecular Cancer 2010, 9:275
http://www.molecular-cancer.com/content/9/1/275
Page 10 of 16Figure 5 Knock-down of Sp1 reveals multiple targets in the p53 signalling pathway are altered. Sp1 knockdown was achieved using
Ambion siRNA. RNA was extracted 48 and 72 hours post transfection, labelled and hybridised to human U133 plus 2.0 arrays. Analysis of
microarray data was carried out using GCOS, Array assist and the DAVID online analysis tool. Statistical significance was determined using an
unpaired two-tailed t test, summarised in the workflow shown in Fig 5A. Knockdown was confirmed by QPCR using TaqMan® gene expression
assays (Fig 5B). Due to variability in knockdown produced by transient transfections, the biological replicates are shown as individual bars. The
gene list identified using PLIER was sorted for statistically significant (p > 0.05) gene expression changes of greater than 1.2 fold. Subsequent
analysis of this list using DAVID identified a number of changes occurring in the p53/P21 regulatory pathway (panel C; adapted from DAVID
[[39,40], and http://www.genome.jp/kegg/). Stars denote genes which were significantly upregulated (red) or down-regulated (black). Validation
of a subset of genes was carried out using Applied Biosystems TaqMan® gene expression assays, according to manufacturer’s instructions. QPCR
expression data for Bid, p21, serpine, P53AIP and Sp1 are shown in Fig 5, panel B for HCT116 cells following Sp1 knockdown harvested 48 (panel
Di) or 72 (panel Dii) hours post-transfection. The biological replicates are shown as individual bars; designated n1 and n2.
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Page 11 of 16post Sp1 knockdown P53AIP mRNA expression was
increased by 1.94% relative to mock in biological repli-
cate 1 (n1) but decreased by 79.2% in the second repli-
cate (n2). These contradicting data may reflect greater
restoration of function in one replicate as Sp1 expres-
sion is higher in replicate 2, indicating that the Sp1
siRNA knockdown is in decline.
Discussion
Numerous in vitro studies have shown that butyrate, at
physiological concentrations, triggers cell cycle arrest and
apoptosis, observations which underpinned the hypoth-
esis proposed by the EPIC team - that butyrate is a prin-
cipal chemopreventive effector of fibre consumption.
Butyrate is an HDACi at physiological concentrations
and although there is considerable interest in the devel-
opment and application of HDACi in cancer therapy and
prevention, the underlying mechanisms of action remain
unclear. Work addressing the molecular pharmacology of
cell cycle arrest showed a p53 independent activation of
p21 expression was a central event in cell cycle arrest
[30,35-37]. In studies addressing the molecular mechan-
isms by which butyrate induces apoptosis, we noted that
this appeared to be independent of cell damage and
resultant signalling. We proposed a model whereby Bak
upregulation by butyrate is a key contributory mechan-
ism in the cancer-preventive properties of fibre [9]. More
recent in vivo studies have confirmed a central role for
Bak in colorectal carcinogenesis in mice [38]. The up-
regulation of both Bak and p21 by butyrate appears to be
due, at least in part, to inhibition of promoter binding by
Sp1, allowing access to the promoter region by Sp3 to
drive transcription. How might such a change in binding
be effected? We showed that binding of Sp1 to its target
sequence site is diminished following butyrate treatment,
in a concentration-responsive manner. A new antibody
to acetyl-Sp1 shows that acetylation of Sp1 increases in a
concentration-dependent manner in response to butyrate
exposure.
An HCA approach was used to determine the dose-
response curves for Sp1 acetylation and Bak up-regulation.
The curves are very similar, resulting in similar EC50
values. In contrast, the p21 curve was shifted to the right
and gave a higher EC50 value, although further work is
required to determine whether real EC50 differences occur
between Sp1, Bak and p21. However, the difference in p21
EC50 could be attributable to a composite effect of p21
transcriptional up-regulation, and nuclear relocalisation.
The p21 promoter is also more complex relative to the
bak promoter, therefore EC50 differences may reflect dif-
fering Sp1/Sp3 binding potentials at these binding sites.
The gating analysis suggests that Sp1 acetylation precedes
p21 up-regulation. We therefore hypothesize that p21-
upregulation is mediated, atl e a s ti np a r t ,t h r o u g ht h e
decreased binding of the p21 promoter by Sp1, perhaps
allowing access to a weaker affinity stronger transactivator.
We and others have previously hypothesized that Sp3 may
fulfil such a function.
We assessed the effect of multiple members of the
HDACi family on cell cycle progression and on expres-
sion of p21. Cell cycle arrest associated with p21 is
more frequently associated with G1 arrest. Our data
indicate that a G2/M arrest is consistently observed
with several of the HDACi used. The pattern of cell
cycle arrest did not correlate with compound class, with
subsets of the SCFA and hydroxamic acids triggering
G1 arrest. Whilst our findings do not imply causality,
there is consistency between p21 upregulation and G2/
M arrest as indicated by similar EC50.I nc o n t r a s tc o m -
pounds which triggered primarily G1 arrest did not
induce p21 expression. This may imply value in investi-
gation of further roles for p21 at other phases of cell
cycle. The degree to which each HDACi may sustain
alterations in Sp1 acetylation (differences were more
pronounced at 24 h than 6 h) could be a contributory
factor to differences observed. For example APHA and
CHAHA both triggered an observable alteration in Sp1
acetylation at 6 h, but in contrast to other hydroxamic
acids the effect had passed by 24 h. It may be that the
persistence of Sp1 acetylation determines the pattern of
cell cycle arrest.
Our microarray analysis following Sp1 knockdown
revealed that reducing Sp1 promoter occupancy by siRNA
knockdown altered the regulation of a number of genes
involved the p53 signalling pathway. These data indicate
that reduced promoter occupancy by Sp1, similar to that
observed following acetylation of Sp1, can influence cell
cycle/death decisions. We noted in our analysis of the
array data that Bak was not altered sufficiently to reach
the threshold for inclusion in the analysis. Our previous
data [9] showed that at the transcriptional level, changes
in Bak mRNA were modest, but consistent across several
assays and we hypothesized that this was sufficient to
unbalance the cell and drive apoptosis. Other genes, for
example Bid, were identified as larger fold changes in this
study and may synergise with alterations in Bak to yield an
apoptosis-susceptible cell. Furthermore, these data demon-
strate that p53 controlled pathways can be regulated by
alteration of Sp1 promoter occupancy, indicating that a
complex interaction occurs between these two transcrip-
tion factors.
The colon epithelial cell exists bathed in high levels of
butyrate. Cell turnover rates in the colon are high with
movement from the stem cell to apoptosis from the flat
musosa in 3-4 days. During this period the cell will pro-
liferate, arrest, differentiate and die, relying on butyrate
to drive the sequence of these events through a highly
coordinated set of transcriptional responses. Low levels
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fibre consumers, would result in lower levels of Sp1
acetylation, resulting in less cell death and more prolif-
erating cells in the colon as a consequence of reduced
Bak and p21 expression. A second pro-carcinogenic
pathway could be associated with the low-butyrate set-
ting: the lower expression of pro-apoptotic protein,
would result in a cell less likely to die in response to a
fixed amount of cytotoxic damage. These pathways
(impaired physiological cell turnover and reduced ability
to respond to damage) could contribute to increased
cancer risk. One limitation of this study is that it is
undertaken in vitro with a cancer-derived cell line. Our
ongoing studies are testing the hypothesis raised - that
Sp1-HDAC interaction may be central to the cancer
preventive actions of butyrate through engagement of
specific target genes - in cross sectional studies invol-
ving human volunteers. Our work thus far highlights the
key role acetylation plays in the regulation of colonocyte
cell cycle. Furthermore there is a need for specific
HDAC inhibitors for the treatment of cancers arising in
this cell population.
Conclusions
￿ Acetylation of Sp1 reduces affinity for the Bak and
p21 promoters, leading to upregulation.
￿ Sp1 is acetylated in response to multiple HDACi.
￿ Acetylation of Sp1 may represent a common
mechanism for induction of cell death and cell cycle
arrest pathways.
Methods
Cell culture
HCT116 cells were used throughout. Cells were grown
in 1 g/L glucose DMEM (Gibco), supplemented with
10%v/v FCS (BioSera, E. Sussex, UK), 0.1 mg/ml strepto-
mycin and 100 U/ml penicillin (Gibco). For treatment
with butyrate, cells were grown to 40-50% confluency.
Growth medium was discarded and replaced with 1 g/L
glucose DMEM (Gibco, Paisley, Scotland), supplemented
with 10%v/v FCS, 0.1 mg/ml streptomycin, 100 U/ml
penicillin (Gibco) and 0-20 mM sodium butyrate (Cal-
biochem, Nottingham, UK).
High-Content Analysis
HCT116 cells were seeded in 96 well plates at 8 × 10
3 cells
per well. 24 hours after seeding the medium was replaced
with growth medium supplemented with 0-10 mM
sodium butyrate. Cells were treated for 24 hours before
being fixed in 3.7% formalin and stained for Bak and Sp1
or acetyl-Sp1 and p21. All antibodies were diluted in
500 μg/ml digitonin/PBS solution according to Imagen
Biotech proprietary HCA protocols. Antibodies used were:
Sp1 (Cat# 07-645, Millipore), p21 (Cellomics p21 Kit,
Thermo Fischer), Bak (Cat# 556396, BD Biosciences) and
a custom antibody to acetylated Sp1. Cross reactions were
visualised using fluorophore conjugated seconday antibo-
dies: donkey anti-mouse (Alexa fluorophore 488 - green)
and donkey anti-rabbit (Alexa fluorophore 555 - red).
DNA was stained with Hoechst 33342 at 2.5 μg.mL
-1.
Plates were analysed on a Cellomics Arrayscan. The
Arrayscan Compartmental Analysis algorithm was used to
generate, a mask to measure either cytoplasmic or nuclear
staining for each fluorescent signal.
Protein Methods
Protein extraction and quantitation
Following treatment, nuclear extracts for DNA binding
assay were prepared using Active Motif nuclear extract
kit (cat#40010, Active Motif, Rixensart, Belgium) as per
manufacturer’s instructions. Cells for whole cell lysate
extraction were washed twice in PBS, and lysed in lysis
b u f f e r( 5 0m MT r i s ,p H7 . 4 ,1m ME D T A ,1 5 0m M
NaCl, 1 mM sodium orthovanadate, 0.5% NP-40, pro-
tease inhibitors (0.1 mM phenylmethylsulfonyl fluoride,
Sigma protease inhibitor cocktail), and 100 mM sodium
butyrate to inhibit HDAC activity. All reagents were
from Sigma (Poole, UK) except for butyrate, which was
as above.
Protein concentrations were quantified using the
BioRad protein assay (cat#500-0006, BioRad, Hertford-
shire, UK) as per manufacturer’s instructions.
Western blotting
Proteins were separated on SDS-PAGE gels and trans-
ferred to PVDF for immunoprobing. After blocking non-
specific binding sites overnight with 5% nonfat milk in
TBST (Sigma), the membrane was incubated for 1 h at
room temperature with primary antibody solutions in
block. The membranes were subject to 3 × 10 min
TBST washes following each antibody incubation. Anti-
bodies used include: HRP conjugated mouse anti-Actin
(ab20272, Abcam), rabbit anti-Sp1 (cat#07-645, Milli-
pore), rabbit anti-Sp3 (D-20, Santa Cruz Biotechnology);
rabbit anti-acetyl lysine (cat#ab3879, Chemicon); mouse
anti-HDAC1 (cat#05-614, clone 2e10, Millipore); mouse
anti-HDAC2 (cat#05-814, clone 3F3, Millpore); rabbit
anti-HDAC3 (ab16047, Abcam). Cross-reactions were
visualized using HRP-conjugated secondary antibodies
(Dako, UK), Immobilon Western HRP substrate (Milli-
pore, UK) and a Chemigenius BioImaging system (Syn-
gene, Cambridge, UK). The antibody to acetylated K703
of Sp1 was commissioned from Eurogentec to the
sequence previously established [3]. The antibody was
double-affinity purified - both counter purified against
the non-acetyl epitope and positively purified against the
acetyl epitope.
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Electromobility shift assays (EMSAs) were conducted
using the lightshift EMSA kit from Pierce (Cat#20148,
Pierce, Rockford IL USA). An adapted version of
the EMSA protocol, a western of a mobility shift gel
(WeMSA) was carried out as previously described [9].
Briefly: unlabelled oligonucleotides were incubated with
nuclear extracts as per Lightshift EMSA kit instructions;
complexes were separated by molecular weight using 5%
TBE acrylamide mini-gels in 0.5 × TBE; gels were incu-
bated in SDS buffer (25 mM Tris; 192 mM glycine; 0.2%
(w/v) SDS) for 10 min prior to being transferred to PVDF
at 100 V for 1 h in 0.5 × TBE; membranes were blocked
in 5% milk TBST for 1 h prior to immunoprobing and
ECL detection of HRP conjugated secondary antibodies.
Oligonucleotides for binding assays were commissioned
from Sigma Genosys. Oligonucleotides used for EMSA
were 3’ biotin-labelled.
siRNA delivery
Sp1 knockdown
Our initial siRNA experiments identified problems with
the commercial negative control and showed that mock
transfected cells were a better control. Therefore for the
microarray experiments cells were transfected with Sp1
(Cat No. AM16704, ID 143158) siRNA or mock trans-
fected. Transfections were carried out at the time of
plating (forward transfection) using Lipofectamine RNAi
max (Invitrogen), according to the manufacturer’s proto-
col for transfecting 24 well plates. 3 × 10
4 HCT116 cells
and a final siRNA concentration of 10 nM were used.
Twelve wells for each transfection condition were trans-
fected to ensure enough RNA was available for both
QPCR and microarray analysis, these were pooled prior
to RNA extraction. Samples were collected 48 h and
72 h post transfection to examine the downstream
effects of Sp1 knockdown. Trizol reagent (Invitrogen)
was used to extract total RNA.
Bioinformatic Approaches
RNA Quality checks
RNA quantity was determined using a NanoDrop 1000
spectrophotometer (Labtech International, East Sussex,
UK). The 2100 bioanalyzer,RNA 6000 Nano LabChip
(Agilent, Palo Alto, CA) was used to assay RNA integ-
rity and samples were only taken forward if the quality
was satisfactory as indicated by the absence of ribosomal
RNA degradation.
Microarray analysis
Double stranded cDNA was synthesised and then in vitro
transcribed to produce biotin-labeled cRNA (GeneChip
Expression 3_-Amplification reagents for in vitro tran-
scription labeling; Affymetrix, Santa Clara, CA). The
amplified cRNA wasthen analyzed for quality (Agilent
2100 Bioanalyzer, RNA 6000 NanoLabChip) and quantity
(NanoDrop 1000 Spectrophotometer). 15 μgo fc R N A
was fragmented (Gene-Chip reagents; Affymetrix) and
hybridized to Human Genome U133 Plus 2.0 GeneChip.
Four chips (2 mock transfected; 2 Sp1 siRNA transfected)
were hybridized for each time point according to Affyme-
trix protocols. After overnight hybridizationat 42°C, the
GeneChips underwent stringency washes in a GeneChip
Fluidics Station 400 (Affymetrix) and were scanned with
a laser at high resolution (GeneChip Scanner 3000; Affy-
metrix). The results were analyzed initially using Gene-
Chip operating software (GCOS), which automatically
acquires and analyzes image data and computes an inten-
sity value for each transcript. The data were subsequently
processed using ArrayAssist (Iobion Informatics, La Jolla,
CA) to statistically analyze changes in gene expression in
the presence of the Sp1 knockdown at each time point.
Transcripts were defined as differentially expressed
between mock and Sp1 siRNA transfected cells if there
was a 1.2 fold or greater difference in the gene expres-
sion level, plus a p value of less than 0.05. The statistical
test applied by the ArrayAssist program was an unpaired
two-tailed t test.Differentially expressed probe sets were
classified according to their molecular function, biologi-
cal process, cellular compartment and chromosomal
location using GeneOntology terms. To identify specific
pathways affected by Sp1 knockdown, the DAVID bioin-
formatics database was also used http://david.abcc.
ncifcrf.gov/home.jsp[39,40].
Quantitative PCR
Prior to reverse transcription amplification grade DNAse
(Invitrogen) was used to eliminate any genomic DNA
contamination. Reverse transcription was carried out
using the superscript III reverse transcriptase (Invitrogen)
and random hexamers (Promega) as per manufacturers’
instructions. QPCR was used to confirm Sp1 knockdown
prior to microarray hybridisation and to validate gene
changes as identified by microarray analysis.
The ΔΔCt real time PCR method [41] was used to quan-
titate gene expression using Applied Biosystems Taqman
gene expression assays and mastermix. The protocol used
was carried out as per manufacturers instructions in 20 μl
reactions.
Additional material
Additional file 1: Data includes diagrams of structures of HDACi
used in this study, antibody validation work, gating strategy for
HCA analysis, additional controls supporting Fig 4B, and graphs of
levels of apoptosis triggered by HDACi used in this paper.
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